
Brief intro:
- Author: QIROU WU, XIAOHONG LENG, QIAN ZHANG, YE-ZHANG ZHU, RUYUAN ZHOU, YUTONG LIU, CHEN MEI , DAN ZHANG, SHENGDUO LIU, SHASHA CHEN, XIAOJIAN WANG, AIFU LIN, XIA LIN, TINGBO LIANG, LI SHEN, XIN-HUA FENG, BING XIA, AND PINGLONG XU
- Journal: SCIENCE ADVANCES
- Doi: https://www.doi.org/10.1126/sciadv.adj2102
- Publication Date: 2024 Feb 28
Products/Services used in the paper
Quotation shows PackGene:HSC- specific deletion of IRF3 was obtained by injection of AAV8 bearing GFAP (promoter)EGFP- Cre into Irf3flox/flox mice through tail vein injection at a dose of 1 × 1011 virus genome (PackGene Biotech), twice in 2 weeks.
Research Field:liver fibrosis
AAV Serotype:AAV8
Targeted organ:liver
Animal or cell line strain:mice
Abstract
Cytosolic double-stranded DNA surveillance by cyclic GMP-AMP synthase (cGAS)–Stimulator of Interferon Genes (STING) signaling triggers cellular senescence, autophagy, biased mRNA translation, and interferon-mediated immune responses. However, detailed mechanisms and physiological relevance of STING-induced senescence are not fully understood. Here, we unexpectedly found that interferon regulatory factor 3 (IRF3), activated during innate DNA sensing, forms substantial endogenous complexes in the nucleus with retinoblastoma (RB), a key cell cycle regulator. The IRF3-RB interaction attenuates cyclin-dependent kinase 4/6 (CDK4/6)–mediated RB hyperphosphorylation that mobilizes RB to deactivate E2 family (E2F) transcription factors, thereby driving cells into senescence. STING-IRF3-RB signaling plays a notable role in hepatic stellate cells (HSCs) within various murine models, pushing activated HSCs toward senescence. Accordingly, IRF3 global knockout or conditional deletion in HSCs aggravated liver fibrosis, a process mitigated by the CDK4/6 inhibitor. These findings underscore a straightforward yet vital mechanism of cGAS-STING signaling in inducing cellular senescence and unveil its unexpected biology in limiting liver fibrosis.
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
